Dr. Choi’s research aims to develop a novel, electronic-based platform that can selectively detect individual target biomarkers of pancreatic cancer in blood by integrating cutting-edge nanotechnology and cancer biology. This research will offer a highly reliable, accurate, automated identification and classification strategy of pancreatic cancer, allowing early-detection, prediction of organ-specific metastasis, and selection of an effective, specific therapeutic plan for the pancreatic cancer patients.
Dr. Kim's research is focused on investigating the perivascular heterogeneity in Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment (TME). The research is aiming to identify novel mechanisms to reprogram the perivascular signature that will promote vascular functionality and enhance drug delivery efficacy. The Kim group utilize in vitro cell culture system to study mechanistic details and animal model system including various Genetically Engineered Mouse Models (GEMM), to evaluate the efficacy of new findings in vivo.
Dr. Mohi Quadir is aiming to develop spatially and temporally-responsive drug delivery nano carriers for pancreatic cancer. The Quadir group is involved in designing linear and dendritic block copolymers that forms nano-sized polymersomes and vesicles capable of encapsulating frontline chemotherapeutic agents and trafficking them to specific cellular compartments without triggering off-target toxicity.